NASDAQ: ALGS
Aligos Therapeutics, Inc.
Healthcare · Biotechnology
Pre-market: $7.10(+1.43%) · as of 4:22 AM ET
Market Cap
$43.32M
52w High
$13.69
52w Low
$3.98
P/E
-0.96
Volume
189.21K
Outstanding Shares
6.19M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 5.91% over the last year. Revenue grew 893.01% over the trailing twelve months. Operating margin moved from -2,473.35% to -250.63%. Free cash flow declined 25.82% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -250.63%. A decisive move in revenue — currently up 893.01% — would be the clearest signal to resolve the ambiguity.
Company profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases.
Valuation
Stock splits
Every 25 shares became 1
Profitability & growth
Analyst consensus
3
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est -$2.44 · Revenue est $4.85M
View